SEOUL,South Korea,Jan. 14,2025-- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for \'Pemziviptadil (development code name PF1804),\' a treatment for DMD (Duch
Free registration with generous rewards! High winning rate,and professional project guidance throughout the entire process!
TAIPEI,Jan. 14,2025-- Infortrend® Technology,Inc. (TWSE: 2495),the industry-leading enterprise storage provider,introduces the latest additions to its high-density 4U 90-bay HDD solutions: unified
Harnessing AI to Revolutionize Hong Kong\'s Publishing Industry: Innovation,Efficiency,and Global Reach
RIYADH,Saudi Arabia,Jan. 14,2025-- The Fourth Ministerial Roundtable meeting began today as part of the Future Minerals Forum,hosting government representatives from 90 countries,including 16 G20 nat
Inaugural study of employees in 23 geographies reveals employees are engaging in a "hustle reset" as they reassess where and how much they work